Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patient has not received Vimpat® more than 7 days prior to start of Non-Interventional Study (NIS)~* The patient must have a diagnosis of epilepsy with partial-onset seizures with or without secondary generalization~* Based on the physician's clinical judgment, it is in the patient's best interest to be prescribed adjunctive Vimpat® (ie, the decision to prescribe Vimpat® is made by the physician)~* Patient must be at least 18 years of age~* The patient must have had at least one seizure within the last 3 months prior to enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vimpat + Na Channel Blocking AED (Type: None): Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs) to include at least 1 sodium channel blocking AED.
- Vimpat + Non-Na Channel Blocking AED (Type: None): Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs), none of which is a sodium channel blocking AED.

Based on this trial design, predict the completion outcome and termination type (if applicable).